IBD clinical, endoscopic, and laboratory characteristics of patients at the diagnosis of IBD.
| IBD Characteristics . | VEO-PSC-IBD (n = 28) . | PSC-IBD (n = 41) . | P . |
|---|---|---|---|
| Age, median (IQR) | 5.2 (3.7-5.9) | 15.7 (13.3-16.9) | <0.0001 |
| Sex F, n (%) | 10 (36%) | 13 (32%) | 0.79 |
| Family history (IBD), n (%) | 4 (14%) | 3 (7%) | 0.4 |
| Family history (PSC), n (%) | 1 (3%) | 1 (2%) | 1 |
| UC, n (%) | 23 (82%) | 37 (90%) | 0.35 |
| CD, n (%) | 3 (11%) | 1 (2.5%) | 0.29 |
| IBDU, n (%) | 2 (7%) | 3 (7.5%) | 1 |
| Disease location CD, n (%) L2 | 3 (100%) | 1 (100%) | 1 |
| Disease location UC,n (%) | |||
| E1 | 1 (4%) | 0 | 1 |
| E2 | 1 (4%) | 2 (5%) | 1 |
| E3 | 0 | 4 (10%) | 0.13 |
| E4 | 23 (92%) | 34 (85%) | 0.24 |
| PUCAI | 34 ± 16 | 30.5 ± 9 | 0.11 |
| PUCAI, n (%) | |||
| remission < 10 | 5 (20%) | 8 (20%) | 1 |
| mild 10-34 | 5 (20%) | 19 (47.5%) | 0.03 |
| moderate 35-64 | 15 (60%) | 9 (22.5%) | 0.003 |
| severe 65-85 | 0 | 4 (10%) | 0.15 |
| MAYO, n (%) | |||
| 1 | 11 (44%) | 13 (32.5%) | 0.4 |
| 2 | 11 (44%) | 20 (50%) | 0.7 |
| 3 | 3 (12%) | 7 (17.5%) | 0.7 |
| IBD diagnosed, n (%) | |||
| Prior to PSC | 13 (46%) | 15 (36.5%) | 0.61 |
| Concomitantly | 11 (39%) | 19 (46.5%) | 0.62 |
| After PSC | 4 (14%) | 7 (17%) | 1 |
| CRP (mg/L) | 6.5 ± 7.2 | 8.7 ± 14 | 0.48 |
| ESR (mm/hr) | 45.7 ± 26 | 42.5 ± 34 | 0.71 |
| Albumin (g/dL) | 4.18 ± 0.48 | 4.11 ± 0.41 | 0.56 |
| Fecal calprotectin (mcg/g) | 667 ± 734 | 530 ± 480 | 0.48 |
| IBD Characteristics . | VEO-PSC-IBD (n = 28) . | PSC-IBD (n = 41) . | P . |
|---|---|---|---|
| Age, median (IQR) | 5.2 (3.7-5.9) | 15.7 (13.3-16.9) | <0.0001 |
| Sex F, n (%) | 10 (36%) | 13 (32%) | 0.79 |
| Family history (IBD), n (%) | 4 (14%) | 3 (7%) | 0.4 |
| Family history (PSC), n (%) | 1 (3%) | 1 (2%) | 1 |
| UC, n (%) | 23 (82%) | 37 (90%) | 0.35 |
| CD, n (%) | 3 (11%) | 1 (2.5%) | 0.29 |
| IBDU, n (%) | 2 (7%) | 3 (7.5%) | 1 |
| Disease location CD, n (%) L2 | 3 (100%) | 1 (100%) | 1 |
| Disease location UC,n (%) | |||
| E1 | 1 (4%) | 0 | 1 |
| E2 | 1 (4%) | 2 (5%) | 1 |
| E3 | 0 | 4 (10%) | 0.13 |
| E4 | 23 (92%) | 34 (85%) | 0.24 |
| PUCAI | 34 ± 16 | 30.5 ± 9 | 0.11 |
| PUCAI, n (%) | |||
| remission < 10 | 5 (20%) | 8 (20%) | 1 |
| mild 10-34 | 5 (20%) | 19 (47.5%) | 0.03 |
| moderate 35-64 | 15 (60%) | 9 (22.5%) | 0.003 |
| severe 65-85 | 0 | 4 (10%) | 0.15 |
| MAYO, n (%) | |||
| 1 | 11 (44%) | 13 (32.5%) | 0.4 |
| 2 | 11 (44%) | 20 (50%) | 0.7 |
| 3 | 3 (12%) | 7 (17.5%) | 0.7 |
| IBD diagnosed, n (%) | |||
| Prior to PSC | 13 (46%) | 15 (36.5%) | 0.61 |
| Concomitantly | 11 (39%) | 19 (46.5%) | 0.62 |
| After PSC | 4 (14%) | 7 (17%) | 1 |
| CRP (mg/L) | 6.5 ± 7.2 | 8.7 ± 14 | 0.48 |
| ESR (mm/hr) | 45.7 ± 26 | 42.5 ± 34 | 0.71 |
| Albumin (g/dL) | 4.18 ± 0.48 | 4.11 ± 0.41 | 0.56 |
| Fecal calprotectin (mcg/g) | 667 ± 734 | 530 ± 480 | 0.48 |
Continuous data are expressed as mean ± standard deviation unless specified otherwise.
Abbreviations: VEO-PSC-IBD, children with both PSC and IBD diagnosed before age 6; PSC-IBD, children with both PSC and IBD diagnosed after age 6.
Abbreviations: VEO, very early onset; PSC, primary sclerosing cholangitis; IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn disease; IBDU, undetermined inflammatory bowel disease; PUCAI, pediatric ulcerative colitis activity index; ESR, erythrocyte sedimentation rate; CRP, c-reactive protein
IBD clinical, endoscopic, and laboratory characteristics of patients at the diagnosis of IBD.
| IBD Characteristics . | VEO-PSC-IBD (n = 28) . | PSC-IBD (n = 41) . | P . |
|---|---|---|---|
| Age, median (IQR) | 5.2 (3.7-5.9) | 15.7 (13.3-16.9) | <0.0001 |
| Sex F, n (%) | 10 (36%) | 13 (32%) | 0.79 |
| Family history (IBD), n (%) | 4 (14%) | 3 (7%) | 0.4 |
| Family history (PSC), n (%) | 1 (3%) | 1 (2%) | 1 |
| UC, n (%) | 23 (82%) | 37 (90%) | 0.35 |
| CD, n (%) | 3 (11%) | 1 (2.5%) | 0.29 |
| IBDU, n (%) | 2 (7%) | 3 (7.5%) | 1 |
| Disease location CD, n (%) L2 | 3 (100%) | 1 (100%) | 1 |
| Disease location UC,n (%) | |||
| E1 | 1 (4%) | 0 | 1 |
| E2 | 1 (4%) | 2 (5%) | 1 |
| E3 | 0 | 4 (10%) | 0.13 |
| E4 | 23 (92%) | 34 (85%) | 0.24 |
| PUCAI | 34 ± 16 | 30.5 ± 9 | 0.11 |
| PUCAI, n (%) | |||
| remission < 10 | 5 (20%) | 8 (20%) | 1 |
| mild 10-34 | 5 (20%) | 19 (47.5%) | 0.03 |
| moderate 35-64 | 15 (60%) | 9 (22.5%) | 0.003 |
| severe 65-85 | 0 | 4 (10%) | 0.15 |
| MAYO, n (%) | |||
| 1 | 11 (44%) | 13 (32.5%) | 0.4 |
| 2 | 11 (44%) | 20 (50%) | 0.7 |
| 3 | 3 (12%) | 7 (17.5%) | 0.7 |
| IBD diagnosed, n (%) | |||
| Prior to PSC | 13 (46%) | 15 (36.5%) | 0.61 |
| Concomitantly | 11 (39%) | 19 (46.5%) | 0.62 |
| After PSC | 4 (14%) | 7 (17%) | 1 |
| CRP (mg/L) | 6.5 ± 7.2 | 8.7 ± 14 | 0.48 |
| ESR (mm/hr) | 45.7 ± 26 | 42.5 ± 34 | 0.71 |
| Albumin (g/dL) | 4.18 ± 0.48 | 4.11 ± 0.41 | 0.56 |
| Fecal calprotectin (mcg/g) | 667 ± 734 | 530 ± 480 | 0.48 |
| IBD Characteristics . | VEO-PSC-IBD (n = 28) . | PSC-IBD (n = 41) . | P . |
|---|---|---|---|
| Age, median (IQR) | 5.2 (3.7-5.9) | 15.7 (13.3-16.9) | <0.0001 |
| Sex F, n (%) | 10 (36%) | 13 (32%) | 0.79 |
| Family history (IBD), n (%) | 4 (14%) | 3 (7%) | 0.4 |
| Family history (PSC), n (%) | 1 (3%) | 1 (2%) | 1 |
| UC, n (%) | 23 (82%) | 37 (90%) | 0.35 |
| CD, n (%) | 3 (11%) | 1 (2.5%) | 0.29 |
| IBDU, n (%) | 2 (7%) | 3 (7.5%) | 1 |
| Disease location CD, n (%) L2 | 3 (100%) | 1 (100%) | 1 |
| Disease location UC,n (%) | |||
| E1 | 1 (4%) | 0 | 1 |
| E2 | 1 (4%) | 2 (5%) | 1 |
| E3 | 0 | 4 (10%) | 0.13 |
| E4 | 23 (92%) | 34 (85%) | 0.24 |
| PUCAI | 34 ± 16 | 30.5 ± 9 | 0.11 |
| PUCAI, n (%) | |||
| remission < 10 | 5 (20%) | 8 (20%) | 1 |
| mild 10-34 | 5 (20%) | 19 (47.5%) | 0.03 |
| moderate 35-64 | 15 (60%) | 9 (22.5%) | 0.003 |
| severe 65-85 | 0 | 4 (10%) | 0.15 |
| MAYO, n (%) | |||
| 1 | 11 (44%) | 13 (32.5%) | 0.4 |
| 2 | 11 (44%) | 20 (50%) | 0.7 |
| 3 | 3 (12%) | 7 (17.5%) | 0.7 |
| IBD diagnosed, n (%) | |||
| Prior to PSC | 13 (46%) | 15 (36.5%) | 0.61 |
| Concomitantly | 11 (39%) | 19 (46.5%) | 0.62 |
| After PSC | 4 (14%) | 7 (17%) | 1 |
| CRP (mg/L) | 6.5 ± 7.2 | 8.7 ± 14 | 0.48 |
| ESR (mm/hr) | 45.7 ± 26 | 42.5 ± 34 | 0.71 |
| Albumin (g/dL) | 4.18 ± 0.48 | 4.11 ± 0.41 | 0.56 |
| Fecal calprotectin (mcg/g) | 667 ± 734 | 530 ± 480 | 0.48 |
Continuous data are expressed as mean ± standard deviation unless specified otherwise.
Abbreviations: VEO-PSC-IBD, children with both PSC and IBD diagnosed before age 6; PSC-IBD, children with both PSC and IBD diagnosed after age 6.
Abbreviations: VEO, very early onset; PSC, primary sclerosing cholangitis; IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn disease; IBDU, undetermined inflammatory bowel disease; PUCAI, pediatric ulcerative colitis activity index; ESR, erythrocyte sedimentation rate; CRP, c-reactive protein
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
